Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo for rare cancer mutation stalls as study ends early

NCT ID NCT06682806

Terminated Disease control Sponsor: Prelude Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called PRT3789 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have a SMARCA4 gene mutation. The goal was to see if the combination was safe and could shrink tumors. However, the study was terminated early and only enrolled 6 participants, so we have very limited information about how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PRT3789 and pembrolizumab (Keytruda)
What this could lead to
If it works, this combination could offer a new treatment option for people with hard-to-treat cancers that have a specific genetic change (SMARCA4 mutation).
What could go wrong
The study was terminated early and only enrolled 6 people, so there is very little data. It is too early to know if the combination is safe or effective, and it may not work at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms metastatic malignant neoplasm neoplasm Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR ESOPHAGEAL CANCER METASTATIC SOLID TUMOR NON-SMALL CELL LUNG CANCERS SMARCA4 GENE MUTATION

Contacts and locations

Locations

  • Florida Cancer Specialists

    West Palm Beach, Florida, 33401, United States

  • Hospital Universitario Fundacion Jimenez Diaz - Servicio de Oncologia

    Madrid, 28040, Spain

  • IOB - Next Oncology - Hospital Quironsalud Barcelona

    Barcelona, 08023, Spain

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • START Barcelona - HM Nou Delfos

    Barcelona, 08023, Spain

  • Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research

    Nashville, Tennessee, 37203, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.